Summary Surgical specimens from 15 medulloblastoma patients were used to establish early passage cultures. In vitro sensitivity to a battery of cytotoxic agents, including some in current medulloblastoma treatment protocols, was measured. Drug sensitivity was assessed at clinically relevant drug concentrations using the 3H-thymidine uptake method. Tumours were predicted to be sensitive if >37% were killed by exposure to drugs at clinically achievable levels. A poor response to vincristine (Vcr), cis-platin (CDDP), hydroxyurea (HU) Medulloblastoma is an important paediatric brain tumour because of its high incidence and malignant behaviour. The overall disease free survival at 5 years, in patients receiving surgery and craniospinal axis radiotherapy, is approximately 50%. This is considered to be the upper limit of curability by these treatment modalities. Chemotherapy has been shown to be advantageous in selected patient groups either as adjuvant therapy or as treatment of recurrent disease. The value of chemotherapy in the treatment of medulloblastoma will be dependent on the availability and identification of drugs active against this tumour. At present, protocols for chemotherapy usually include the lipophilic compounds carmustine (BCNU) or lomustine and procarbazine. Vincristine (Vcr), whilst poorly absorbed by cerebrospinal fluid and brain, is also commonly used (Bloom, 1986; Workman, 1986) . Currently '8 in 1F therapy is being evaluated (Pendergrass et al., 1987) .
Medulloblastoma is an important paediatric brain tumour because of its high incidence and malignant behaviour. The overall disease free survival at 5 years, in patients receiving surgery and craniospinal axis radiotherapy, is approximately 50%. This is considered to be the upper limit of curability by these treatment modalities. Chemotherapy has been shown to be advantageous in selected patient groups either as adjuvant therapy or as treatment of recurrent disease. The value of chemotherapy in the treatment of medulloblastoma will be dependent on the availability and identification of drugs active against this tumour. At present, protocols for chemotherapy usually include the lipophilic compounds carmustine (BCNU) or lomustine and procarbazine. Vincristine (Vcr), whilst poorly absorbed by cerebrospinal fluid and brain, is also commonly used (Bloom, 1986; Workman, 1986) . Currently '8 in 1F therapy is being evaluated (Pendergrass et al., 1987) .
Cytotoxicity has been assessed by clonal assays in agar or on plastic, incorporation of 3H-thymidine into DNA, uptake of vital dyes and other methods with much the same results. Predictions of resistance are close to 100% correct; prediction of sensitivity, whilst less reliable, still has a success rate of around 70% Moon et al., 1981; Rosenbloom et al., 1983; Bogdahn, 1983; Kornblith et al., 1981; Kimmel et al., 1987) . We have examined drug sensitivity in human medulloblastoma by using 14 early passage cultures. Our study provides data on the degree of heterogeneity of response between medulloblastomas obtained from a number of patients. Furthermore, the cells were from early passage cultures, and hence should give a better indication of chemosensitivity of the tumours in vivo. The epipodophyllotoxins teniposide (VM-26) and etoposide (VP16-213) were identified as potentially useful agents in this disease. We investigated the basis of primary clinical resistance to these drugs by quantitating intracellular steady-state drug concentrations, drug-induced protein-linked DNA strand breaks, and topoisomerase II expression and activity.
Materials and methods

Establishment of cell cultures
All studies were made on material collected at procedures performed for clinical reasons and remaining after sufficient tissue has been taken for clinical laboratory study. The histological diagnosis was confirmed by an independent neuropathologist (Professor B.W. Scheithauer). Over a period of 2 years, 16 medulloblastoma specimens were received from a total of 15 patients. The age of the patients ranged from 3 to 11 years (median 5.5 years) with a male to female ratio of 2:1. Most of the samples were from primary tumours however both a primary tumour (MD 6 ) and a metastasis removed at the same time (MD 6M) were obtained from one patient. A recurrent fourth ventricle tumour (MD 5) was removed 3 years after a patient had completed a full course of craniospinal irradiation and post irradiation chemotherapy and in another patient a frontal metastasis (MD 14) was removed 15 months following extirpation of the primary lesion and a full course of craniospinal irradiation.
Tumours samples were dissociated and cloned in agar as described by Ablett et al. (1984) . Primary cultures, were established in tissue culture flasks from dissociated tumour cells in RPMI 1640 with 10% FCS, were incubated at 37°C in an environment of 5% 02, 5% C02, 90% N2 and 100% humidity. When the monolayers were almost confluent, the cultures were passed. Cultures were characterised around passage No. 4 and against around passage No. 10. Experiments were not performed on cells after 12 passages. They were routinely checked for mycoplasma.
Characterisation of early passage cultures The early passage cultures were characterised by immunohistochemical methods for neuron specific enolase (NSE) (Dako PAP kit, Dako Corp., Santa Barbara, USA) and by a panel of monoclonal antibodies (UJ13A and A2B5 which bind to normal and neoplastic neuroectodermal tissue, UJ18 1.4 which shows specificity to oncofoetal antigen expressed by foetal brain and neuroblastic tumours and UJ127.11 which recognises antigens of normal neuroectodermal tissue, neuronal tumours and schwannomas) all of which were kindly provided by Dr J.T. Kemshead (Brain Tumour Research Laboratory, Frenchay Hospital, Bristol, England) (Coakham et al., 1984) . As frozen material was not available, immunohistochemical staining was not performed on the surgical specimen. Cytogenetic analysis was performed on early passage cultures as described by Sandburg (1980) . Metaphases were G-banded (G-bands with Trypsin and Giemsa). At least five metaphases were examined per culture. DNA flow cytometry was performed as described by Pemble et al. (1987) . Normal HeLa cells were used as control.
Drug testing protocol
A reduction in survival, at clinically achievable drug levels, to 37% was adopted for classifying tumours into sensitive and resistant groups Moon et al., 1981; Lihou & Smith, 1983 & 1985 Kornblith et al., 1981; Rosenbloom et al., 1983; Kimmel et al., 1987) . The pharmacokinetic parameter C x T (concentration time.product) (Mellett, 1974; Alberts et al., 1980) was used as the measure of clinically achievable drug exposure. The C x T achieved in patients receiving standard drug doses was obtained from, or calculated from published data (Tables I, II) . The in vitro C x T required to reduce survival to 37% was calculated simply by multiplying the D37, the drug concentration required to reduce survival to 37% of control values, by the number of hours of incubation i.e. 24 h (Tables I, II) . This was compared with the C x T achievable in patients (Tables  I, II) : tumours were classified as sensitive if the former figure was less than the latter.
The medulloblastoma cells were exposed for 4 h to drugs generally regarded as cycle specific, but not phase-specific (diaziquone (AZQ) cis-platin (CDDP), mafosfamide (Mfs), adriamycin (Adr)) (Chabner & Collins, 1990) . Cells were exposed to BCNU (cycle-specific drug) for 24h, since the drug has a short half-life (t1/2). At 37C, the t1/2 of BCNU in vitro is 12 min (Russo et al., 1987) , hence the drug concentration is close to 0 after about 2 h. It was calculated that a 24 h incubation with 10 .lM BCNU resulted in an in vitro C x T of 2.9 LM.h. The alkylating activity of Mfs in vitro was calculated assuming rapid hydrolysis to 4-OH cyclophosphamide (Niemeyer et al., 1984) and an alkylating activity half-life for 4-OH cyclophosphamide in vitro of 3 h (Draeger et al., 1976) . A 4 h incubation with 20 t4M Mfs results in a C x T for alkylating equivalents of 52 t4M.h. Early passage cultures (Owellan et al., 1977) ; cytosine arabinoside (AraC)-300, 17.7, 22.6 (Ho & Frei, 1971) ; hydroxyurea (HU) -3000 p.o, 1703 , 191 (Davidson & Winter, 1963 ; teniposide (VM-26) - 165, 370, 51.3 (Allen & Creavan, 1975) and etoposide (VP16-213) 100, 103, 17.7 (Allen & Creaven, 1975 (Levin et al., 1978) ; Mfs, derived data from cyclophosphamide pharmacokinetic dose and C x T values -1,200, 1,280 (Grochow & Colvin, 1979) . Expressed as alkylating equivalents C x T and peak plasma concentration values are 139 and 27; cis-platin (CDDP) -90, 5.9, 7.5 (Patton et al., 1978) and diaziquone (AZQ) -9, 4.07 and 0.37 (Lu et al., 1983 ). -Not done.
were exposed to the phase-specific agents i.e. cytosine arabinoside (AraC), hydroxyurea (HU), and 107 cells were used to make the lysates which were stored at -20'C following dialysis against 30 mM potassium phosphate pH 7.0, 50% glycerol, 0.5 mM dithiothreitol and 0.1 mM EDTA.
Topoisomerase II activity Topoisomerase II activity of nuclear lysate from medulloblastoma early passage cultures was assessed using the P4 DNA unknotting assay (Liu & Davis, 1981 (Table III) . Of the four specimens submitted for flow cytometry, two were aneuploid (Table III) . indicating that factors other than proliferative status also influenced sensitivity to these agents.
There was a heterogeneous response to the phase-specific agents, with the highest D37 being 40 times (Vcr), 43 times 100,000 r 3 4 5 6 7 9 10 *eduflblastoma ulture (AraC) or 88 times (HU) higher than the lowest measured. The fastest growing early passage culture, MD 12, was by far the most sensitive to all three agents, but no culture was consistently more resistant than others. Spearman rank correlation analysis revealed no significant cross-sensitivity between any combination of these agents. This again indicates that factors other than those affecting cell growth determined in vitro sensitivity.
Only one tumour was considered sensitive to clinically achievable levels of AraC and none to either HU or Vcr (Table I) . A very high concentration of HU was required to kill cells when compared with plasma drug levels.
Sensitivity to epipodophyllotoxins Similar experiments to those described above were carried out using the epipodophyllotoxins VM-26 and VP16-213, nonintercalative topoisomerase II poisons (Liu, 1989) . The response was heterogenous (Table I) ; the range of response to VM-26 being greater than that for any other drug tested. The in vitro response was not related to d.p.m. in control cultures, but sensitivity to VM-26 was highly, significantly correlated with response to VP16-213 (r = 0.852, P<0.002, n = 13) ( Table IV) .
Twelve of 13 (92%) tumours were considered sensitive to clinically achievable levels of VM-26 as were seven out of 13 (54%) to VP16-213 (Table I) . This difference in responsiveness was due to two factors; on a molar basis, VM-26 was far more cytotoxic than VP16-213, and the plasma pharmacokinetics reported for VP16-213 are worse than for VM-26, because lower doses of VP16-213 must be administered and for the same dose the C x T and the peak plasma concentration are lower (Table I) . Most medulloblastoma cells were very sensitive to VM-26. Ten of the sensitive early passage cultures responded at levels which were less than 1/10 of that achievable in patients and for one culture (MD 12) this figure was 1/600. In this regard, VM-26 was the best agent tested in this study.
Three early passage cultures however, were markedly more resistant to VM-26 than average. The D37 values for these cultures were 15.17IAM for MD5; 49.30 ,sm; for MD 7 and 11.60JM for MD 11. These cells were approximately 400-1600 times as resistant as the most sensitive culture (MD 12, D37 0.03 JAM) and 20 to 80 times more resistant than average for the remaining cultures (D37 0.62 JAM ± 0.35 JAM s.d). The same three early passage cultures were also resistant to VP16-213. The difference between sensitive and resistant cultures was not as marked as for VM-26, for D37 for the VP16-213 resistant cultures being around 300 times that of MD 12 and 13 times the average for the other nine early passage cultures.
Sensitivity to alkylating and cross-linking agents Medulloblastoma early passage cultures were also tested for sensitivity to alkylating and cross-linking agents i.e. BCNU, Mfs, CDDP and AZQ (Table II) . A spectrum of responses bNumber of early passage cultures tested.
was observed but the differences between the most sensitive and most resistant cultures (D37 resistant cultures/D37 sensitive culture) were less for this group of agents than for the phase-specific agents. These ratios were five for BCNU, 23 for Mfs, 9 for CDDP and 16 for AZQ.
Early passage cultures resistant to the epipodophyllotoxins (MD 5, MD 6, MD 7 and MD 11) were generally more resistant than average to alkylating agents as well. MD 6 however appeared to be relatively sensitive to AZQ. Again, MD 12 was the most sensitive to all these agents, but as mentioned above, the differences between cultures were not as great for this class of agents.
None of the tumours were sensitive to CDDP or AZQ but seven of 12 were sensitive to BCNU and nine out of ten were sensitive to Mfs (Table II) . In all cases, the level of in vitro drug exposure had to be of the same order of magnitude as the maximum clinically achievable level to reduce survival to 37% of control, untreated cells. In other words, none of the tumours tested were very sensitive to any agent from this group.
Sensitivity to amsacrine (m-AMSA) Sensitivity to a DNA intercalating topoisomerase II poison (M-AMSA) (Liu, 1989) was tested (Figure 2 ). The range of responses to this agent was large, the highest D37 calculated being 399 times the lowest. MD 5 and MD7 were very resistant to this agent, whilst MD 11 was only marginally more resistant than average. Rank correlation analysis revealed significant relationships between sensitivity to this agent and epidodophyllotoxins, and also with Mfs (Table  IV) .
Patterns of cross-resistance and collateral sensitivity As stated previously, the data in Tables I and II was analysed for cross-resistance and collateral sensitivity relationships by the Spearman rank correlation test (Table IV) . Cross resistance between VM-26 and VP16-213 was confirmed. There was also a significant relationship between resistance to these agents and to the other topoisomerase II poison tested, m-AMSA.
There was no apparent relationship between sensitivity to either VM-26, VP16-213 or m-AMSA and Vcr suggesting that the phenomenon of 'pleiotropic drug resistance' may not be responsible for the patterns of cross-resistance seen. Doseresponse experiments with VM-26 were also performed in the presence of agents known to reverse this type of resistance: verapamil (1O JM) (Yalowich & Ross, 1985) and cyclosporin A (7 and 13 1ig ml-') (Slater et al., 1986) . Neither of these agents significantly altered sensitivity to VM-26 in any of the early passage cultures tested; all cultures were tested except for MD 10 and MD 17. A surprising finding was the association between Mfs sensitivity and response to either VP16-213 or m-AMSA. The relationship with VM-26 was not significant. The only dgent for which sensitivity was significantly linked with the amount of 3H-thymidine incorporation in control cells was AZQ. There was no significant difference between results obtained from MD 6, the primary tumour and MD 6M, a metastasis obtained from the same patient. were calculated as outlined for In medulloblastoma early passage cultures, VM-26 was much more cytotoxic to cells on an equimolar basis than VP16-213 (Table I) . Experiments were performed to compare the number of protein-linked DNA strand breaks produced by Time (h) 
Discussion
The benefits of surgery and radiotherapy for treatment of malignant disease are generally considered to be approaching the maximal attainable limits. Further improvement in disease free survival may be achieved by chemotherapy but there is considerable heterogeneity of response to different agents; both between patients and between tumour types. The present study concentrated on medulloblastoma; a tumour with a poor prognosis but where chemotherapy has been shown to be advantageous for some patients (Evans et al., 1990; Tait et al., 1990; Packer et al., 1991; Bloom, 1986) . We have examined the in vitro sensitivity of early passaged cultures from 13 medulloblastoma patients to a number of drugs. Since the cultures have not been extensively passage, the possibility of selection from an originally heterogenous sample of tumour cells is therefore diminished. The results should give an indication of the degree of heterogeneity of response between different tumours.
The clinical criteria for selection of tumour samples for use in this study were based on: (a) demographic characteristics and clinical presentation; (b) the radiologic appearance; (c) the histologic appearance. The identity of the cultured cells was determined on morphological (Rubinstein & Herman, 1986; Gerosa et al., 1987) immunohistochemical, cytogenetic and DNA flow cgtometric analysis. The immunohistochemical profile was determined using a panel of murine monoclonal antibodies (UJ13A, UJI81.4, UJ127.11 and A2B5). These antibodies have been successfully used for the characterisation of surgical material and established cell lines (Kemshead & Coakham, 1983; Bourne et al., 1986; He et al., 1989; Coakham & Bourne, 1989) .
As with surgical specimens of gliomas (Rosenbloom et al., 1983) , medulloblastoma primary cultures exhibited poor cloning efficiencies in semisolid media in contrast to the high cloning efficiency seen in an established medulloblastoma cell line Daoy (Jacobsen et al., 1985) . However, medulloblastoma is unlike gliomas in that clonal growth on plastic is hard to assess due to cell mobility and poor growth at low cell density. In this study, we used an end-point of cellular 3H-thymidine uptake 5-7 days after drug exposure as an indicator of drug toxicity. This has been found to correlate with clonal growth in agar (Parsons & Brown, 1979) .
The cut-off used for sensitivity in the present study was that found by others to predict clinical response (approxi-I mately 100% correct for resistance, 70% for sensitivity) Moon et al., 1981; Rosenbloom et al., 1983; Bogdahn, 1983; Kornblith et al., 1981; Kimmel et al., 1987) ; except that the D37 rather than D4, was used. The parameter used as a measure of maximum possible in vivo drug exposure (in the clinical situation) was the C x T (drug concentration x duration of exposure). This is considered to be a more relevant pharmacokinetic parameter than concentration or duration of exposure alone in determining response to drugs (Mellett, 1974; Alberts et al., 1980 ). The C x T of in vitro exposure was calculated to parallel reported in vivo C x T values. Exposures of 4 h duration were used for drugs which are not phase-specific. A 24 h incubation was used for drugs which demonstrate phase-specificity and have relatively long plasma half-lives. This approach has been successful in this laboratory in studies of acute myeloid leukaemia (Lihou & Smith, 1985) . We (Issell et al., 1982 (Weisenthal, 1981; Tveit et al., 1981) .
Additionally, Friedman et al. (1988) A number of authors have characterised the basis of epipodophyllotoxin resistance in non-medulloblastoma cell lines and found it to be due to alterations in drug transport and associated with 'pleiotropic drug resistance' (Yalowich & Ross, 1985 (Zwelling, 1985) . The level of protein-linked DNA breaks is most closely associated with cytotoxicity (Rowe et al., 1986) , whilst inhibition of enzyme actually appears to be less important. (Pommier et al., 1986; Per et al., 1987) . This, however, is not always the case. It has been proposed that an alteration of activity (Glisson et al., 1986) or differential activity of two different forms of the enzyme explains decreased protein-linked DNA strand breaks in resistant cells . More recently, a second form of topoisomerase II, the p180 form, or topoisomerase II P has been characterised and this may explain non-MDR mediated resistance to topoisomerase II a inhibitors (Drake et al., 1989) . We have identified heavier forms of topoisomerase II in MD 7. However, the topoisomerase II P form described is not identified by the monoclonal antibody used in this study. This suggests that the heavier form identified in MD 7 may be transformed topoisomerase II a (Dr L.F. Liu, personal communication) . Further characterisation of these forms is beyond the scope of this study. (Wyllie, 1987) . After 24 h continuous exposure to VM-26 the precipi- In conclusion, our study demonstrates a heterogeneity of response of a number of early passage medulloblastoma cultures to the chemotherapeutic agents tested. The epipodo-phyllotoxins, in particular VM-26, were the best class of chemotherapy agents tested, while some drugs in clinical use, were found to be ineffective. In vitro chemosensitivity testing of early passage medulloblastoma cultures, more representative of the tumour than established cell lines, provides a method for the selection of agents for use in chemotherapy regimens. With the current trend for pre-irradiation chemotherapy and use of chemotherapy alone in babies and very young children, this should be a valuable method, but the time interval necessary to test a battery of chemotherapeutic agents and the limited amount of material often available for multiple drug testing detract from its clinical applicability. Manipulation of early passage cultures, with cell growth factors, providing that this does not induce changes in genotype, may provide a rapid in vitro method which would allow selection of a patient specific chemotherapy protocol.
